Project Grant R41DK142395
Award Date 9/7/25
Completion Date 8/31/26
Dollars Obligated $372K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,258 to The Leland Stanford Junior University to conduct research aimed at advancing cell-based therapies for Type 1 Diabetes Mellitus (T1D). The key objectives are to: 1) establish effective, non-toxic strategies to induce immune tolerance toward donor tissues for islet cell...
- This $3,140,632 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The 4-year project, awarded to the Regents of the University of California, San Francisco, seeks to enhance the...
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,093,967 Project Grant to Persista Bio Inc. in Ithaca, NY. The grant supports the advanced preclinical development of the O2Line system, an oxygenated cell encapsulation device for type 1 diabetes cell replacement therapy. The goal is to develop a safe, anti-fibrotic, and high-capacity cell delivery system that...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $509,265.00 to Cornell University to develop a cell-retaining, subcutaneous device that allows blood vessel penetration and establishment of an immunotolerant environment for islet delivery for type 1 diabetes cell replacement therapy. The goal is to create a cell delivery...
- This federal Project Grant award of $641,794 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the mechanisms that protect beta-cells from DNA damage during periods of growth and adaptation, in order to maintain beta-cell homeostasis and prevent the loss of functional beta-cells, a key factor in the development of type 1 and type 2...